Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Antiemetics  (2)
  • Cancer  (1)
  • Dexamethasone  (1)
  • 1
    ISSN: 1433-7339
    Keywords: Antiemetic ; 5-HT3 receptor antagonist ; Dexamethasone ; Efficacy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5-HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high-dose cisplatin chemotherapy and to ascertain whether continuation of granisetron after 24 h reduces the occurrence of delayed emesis. This randomised, double-blind, multicentre, three-arm study was conducted at 21 medical centres. A group of 292 nausea- and emcsis-free patients with cancer, who had never had chemotherapy and were scheduled to receive at least 50 mg/m2 cisplatin, were given 3 mg granisetron i.v. in a 15-min infusion with or without 10 mg dexamethasone i.v. completed 5 min prior to high-dose cisplatin and 1 mg granisetron p.o. at +6 h and +12 h. Primary study end-points were control of emesis and nausea. Patients completed a self-report diary every 6 h for the first 24 h. At the end of the 24-h period, the patients who received dexamethasone had a significantly higher complete protection rate from emesis (64% compared to 39%) than those who received no steroid. Similarly, the dexamethasone-treated group had a significantly higher complete plus partial (0–2 emetic episodes) protection rate (84% compared to 64%). This study shows that dexamethasone markedly enhances the antiemetic efficacy of granisetron for acute-onset emesis in high-dose cisplatin chemotherapy.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Supportive care in cancer 5 (1997), S. 12-16 
    ISSN: 1433-7339
    Keywords: Guidelines ; Antiemetics ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Major breakthroughs in the treatment of chemotherapy-induced emesis have come through the use of selective 5-HT3 receptor antagonists in combination with corticosteroids. This combination can be considered standard for most but not all commonly used chemotherapeutic agents. Delayedonset emesis remains a problem, particularly for patients receiving high-dose cisplatin. There is debate over the value of using selective 5-HT3 receptor antagonists beyond the first 24 h. Clinical trials have not settled this uncertainty, although it seems likely that they add only modestly to the effect of corticosteroids. For both the acute and delayed phases, dopamine receptor antagonists may add to the effectiveness of antiemetic therapy. This article outlines a strategy for initial antiemetic therapy and the rationale for the recommendations.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Supportive care in cancer 5 (1996), S. 12-16 
    ISSN: 1433-7339
    Keywords: Key words Guidelines ; Antiemetics ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Major breakthroughs in the treatment of chemotherapy-induced emesis have come through the use of selective 5-HT3 receptor antagonists in combination with corticosteroids. This combination can be considered standard for most but not all commonly used chemotherapeutic agents. Delayed-onset emesis remains a problem, particularly for patients receiving high-dose cisplatin. There is debate over the value of using selective 5-HT3 receptor antagonists beyond the first 24 h. Clinical trials have not settled this uncertainty, although it seems likely that they add only modestly to the effect of corticosteroids. For both the acute and delayed phases, dopamine receptor antagonists may add to the effectiveness of antiemetic therapy. This article outlines a strategy for initial antiemetic therapy and the rationale for the recommendations.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1433-7339
    Keywords: Key words Quality of life ; Chemotherapy ; Cancer ; Nausea ; Vomiting
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  The purpose was to measure the effects of postchemotherapy nausea and vomiting (PCNV) on health-related quality of life (HQL) in patients receiving either moderately or highly emetogenic chemotherapy. The study sample consisted of 832 chemotherapy-naive patients with cancer who received either moderately or highly emetogenic chemotherapy as part of multicenter trials of new antiemetics. The patients completed the self-report European Organization for Research and Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) before chemotherapy (baseline) and 1 week (day 8) and 2–4 weeks after chemotherapy. They also completed a self-report nausea and vomiting (NV) diary for 5–7 days after chemotherapy. To determine the effects of PCNV on HQL, the change in scores between the baseline and day 8 HQL assessments was calculated for each domain and symptom in the QLQ-C30 and compared in four subgroups of patients: those with both nausea and vomiting, those with nausea but no vomiting, those with no nausea but with vomiting, and those with neither nausea nor vomiting. The group with both nausea and vomiting showed statistically significantly worse physical, cognitive and social functioning, global quality of life, fatigue, anorexia, insomnia and dyspnea as compared to the group with neither nausea nor vomiting (0.0001〈P〈0.05). Patients with only nausea but no vomiting tended to have less worsening in functioning and symptoms than those having both nausea and vomiting. Increased severity of vomiting (〉2 episodes) was associated with worsening of only global quality of life and anorexia as compared with 1–2 episodes of vomiting (0.0001〈P〈0.01). By 2–4 weeks after chemotherapy all HQL scores had either returned to their baseline levels or were better than baseline. PCNV adversely affects several quality-of-life domains, but patients with only nausea experience less disruption than do those with both nausea and vomiting. Patients with 1–2 episodes of vomiting experience almost the same degree of disruption of HQL as do patients with more than 2 episodes of vomiting.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...